Phase 2a RSV Challenge Study Planned for Q3 2017
Mon, 24/04/2017 - 07:30
Thu, 30/03/2017 - 16:00
London, UK and Washington D.C, USA, 30th March 2017 / Sciad Newswire / Oppilotech Ltd, a biopharmaceutical start-up compa
Thu, 30/03/2017 - 10:00
Cambridge, UK, 30th March 2017 / Sciad Newswire / Domainex Ltd, a privately-owned drug discovery services company, is ple
Wed, 15/03/2017 - 10:10
Moncton, Canada, 15th March 2017 / Sciad Newswire / The Atlantic Cancer Research Institute (ACRI) is pleased to announc
Tue, 21/02/2017 - 07:30
Cleveland, UK, 21st February 2017 / Sciad Newswire / Cambridge Research Biochemicals® (CRB), a longstanding
Wed, 04/01/2017 - 07:00
Prokarium and Probiomed today announced the start of their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks. The first vaccine to be manufactured will be developed to prevent so-called ‘Montezuma’s revenge’ or diarrhoea, which affects the local population as well travellers in Mexico and many countries.
Mon, 05/12/2016 - 07:30
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to announce a collaboration with Sartorius Stedim Cellca (Cellca) to evaluate and test its customised synthetic promoters with Sartorius’ proprietary mammalian production cell platform. The goal of the programme is to reduce timelines and increase yields in the development of stable cell lines for the production of biopharmaceuticals.
Thu, 17/11/2016 - 15:00
Saffron Walden, UK, 17th November 2016 / Sciad Newswire / Saffron Walden, UK, 17th November 2016 / Sir Simon Campbell, CBE FRS FMedSci, was welcomed b
Thu, 17/11/2016 - 14:30
London, UK, 17th November 2016 / Sciad Newswire / The pharmaceutical industry is a sector of strategic importance, standing on the threshold of innovation, sa
Mon, 31/10/2016 - 09:00
ReViral, an antiviral drug discovery and development company developing innovative therapies against Respiratory Syncytial Virus (RSV), announced today the initiation of a Phase 1 clinical trial for RV521, its novel orally-active small molecule inhibitor of RSV fusion.